Taylor A Banks1, Mark Tucker2, Eric Macy3. 1. Division of Allergy/Immunology, Naval Medical Center Portsmouth, Portsmouth, VA, USA. 2. Department of Allergy and Immunology, Naval Branch Health Clinic, San Diego, CA, USA. 3. Department of Allergy, Southern California Permanente Medical Group, Kaiser Permanente, 7060 Clairemont Mesa Blvd, San Diego, CA, 92111, USA. eric.m.macy@kp.org.
Abstract
PURPOSE OF REVIEW: An unconfirmed penicillin allergy is known to confer significant risk to patients. Only a small minority of patients labeled with penicillin allergy will be confirmed to be hypersensitive with the current reference standard test, an oral amoxicillin therapeutic dose challenge. Skin testing has been recommended prior to oral challenges to reduce the risk of severe acute challenge reactions. The rate of severe acute anaphylactic reactions with oral amoxicillin is currently extremely low. Unfortunately, penicillin skin testing, as commonly performed, has a high rate of false positive results. RECENT FINDINGS: Encouraging skin testing in all individuals with an unconfirmed penicillin allergy, prior to a confirmatory oral challenge, would be technically difficult, make testing all individuals with an unconfirmed penicillin allergy very unlikely, and ultimately increase the risk to patients because of suboptimal antibiotic use. Most patients, who are appropriate candidates for a direct oral amoxicillin challenge, to confirm current penicillin tolerance, can be safely identified by their clinical histories. Higher risk individuals, those with a history of anaphylaxis or other acute onset potentially IgE-mediated reaction such as hives within 6 h of the first dose of the last course of a penicillin, may benefit from properly performed puncture and intradermal skin testing, using commercially available penicilloyl-polylysine, prior to an oral challenge, if skin test negative. Direct oral amoxicillin challenges in low-risk individuals are well accepted by patients and a safe and effective part of penicillin allergy delabeling.
PURPOSE OF REVIEW: An unconfirmed penicillinallergy is known to confer significant risk to patients. Only a small minority of patients labeled with penicillinallergy will be confirmed to be hypersensitive with the current reference standard test, an oral amoxicillin therapeutic dose challenge. Skin testing has been recommended prior to oral challenges to reduce the risk of severe acute challenge reactions. The rate of severe acute anaphylactic reactions with oral amoxicillin is currently extremely low. Unfortunately, penicillin skin testing, as commonly performed, has a high rate of false positive results. RECENT FINDINGS: Encouraging skin testing in all individuals with an unconfirmed penicillinallergy, prior to a confirmatory oral challenge, would be technically difficult, make testing all individuals with an unconfirmed penicillinallergy very unlikely, and ultimately increase the risk to patients because of suboptimal antibiotic use. Most patients, who are appropriate candidates for a direct oral amoxicillin challenge, to confirm current penicillin tolerance, can be safely identified by their clinical histories. Higher risk individuals, those with a history of anaphylaxis or other acute onset potentially IgE-mediated reaction such as hives within 6 h of the first dose of the last course of a penicillin, may benefit from properly performed puncture and intradermal skin testing, using commercially available penicilloyl-polylysine, prior to an oral challenge, if skin test negative. Direct oral amoxicillin challenges in low-risk individuals are well accepted by patients and a safe and effective part of penicillinallergy delabeling.
Entities:
Keywords:
Adverse drug reaction; Amoxicillin; Antibiotic stewardship program; Delabeling; Drug allergy; Hypersensitivity; Oral challenge; Penicillin; Skin testing
Authors: Mary L Staicu; David Vyles; Erica S Shenoy; Cosby A Stone; Taylor Banks; Kristin S Alvarez; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-10
Authors: Jason A Trubiano; Monica A Slavin; Karin A Thursky; M Lindsay Grayson; Elizabeth J Phillips Journal: J Allergy Clin Immunol Pract Date: 2019-06-13
Authors: Kyra Y L Chua; Sara Vogrin; Susan Bury; Abby Douglas; Natasha E Holmes; Nixon Tan; Natasha K Brusco; Rebecca Hall; Belinda Lambros; Jacinta Lean; Wendy Stevenson; Misha Devchand; Kent Garrett; Karin Thursky; M Lindsay Grayson; Monica A Slavin; Elizabeth J Phillips; Jason A Trubiano Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079
Authors: Anna R Wolfson; Christian M Mancini; Aleena Banerji; Xiaoqing Fu; Allison S Bryant; Neelam A Phadke; Erica S Shenoy; Weaam Arman; Yuqing Zhang; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-11-16
Authors: Jason A Trubiano; Sara Vogrin; Kyra Y L Chua; Jack Bourke; James Yun; Abby Douglas; Cosby A Stone; Roger Yu; Lauren Groenendijk; Natasha E Holmes; Elizabeth J Phillips Journal: JAMA Intern Med Date: 2020-05-01 Impact factor: 44.409